Redeye: Heliospectra - All eyes on 2025
Redeye updated its estimates and fair value range following Heliospctras Q3 2024 report, in which sales matched our forecast, but the margins and order intake were softer. With the new greenhouse solutions now in place, the focus is on ramping up commercialisation efforts to secure larger projects (exceeding SEK50m) for the 2025 greenhouse season. Our new Base case fair value is SEK1.2 (SEK1.3) per share.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/